Acepodia Biotech, Inc.
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- Conditions
- IgG4 Related Disease
- Interventions
- Drug: Lymphodepleting chemotherapy
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT07061938
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06415487
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸SCRI Denver Drug Development Unit, Denver, Colorado, United States
🇺🇸Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee, United States
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
- Conditions
- B-cell LymphomaNon Hodgkin LymphomaDLBCLPrimary Mediastinal Large B Cell LymphomaMarginal Zone LymphomaFollicular LymphomaBurkitt LymphomaHigh-grade B-cell Lymphoma
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05653271
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
🇨🇳Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Ministry of Health and Welfare Shuang-Ho Hospital, New Taipei City, Taiwan
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
- Conditions
- HER2-positive Gastric CancerHER2-positive Metastatic Breast CancerLocally Advanced Solid TumorSolid TumorMetastatic Cancer
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04319757
- Locations
- 🇺🇸
Northwestern Univeristy, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳Taipei Veteran General Hospital, Taipei, Taiwan